Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells

Cancer Letters

Volumn 195, Issue 1, 2003, Pages 101-109

  Denkert, Carsten ^a   Koch, Ines ^a   Berger, Stefan ^a   Köbel, Martin ^a   Siegert, Antje ^a   Hauptmann, Steffen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Invasion; Matrix metalloproteinases; Ovarian carcinoma

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTIINFLAMMATORY AGENT; CYTOKINE; ENZYME INHIBITOR; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MATRIGEL; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL; CANCER CONTROL; CANCER INVASION; CANCER THERAPY; CELL ASSAY; CELL INVASION; CELL LINE; CELL STIMULATION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; ENZYME SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 0038059236     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00052-1     Document Type: Article

References (29)

1. Greenlee R.T., Murray T., Bolden S., Wingo P.A. Cancer statistics. Ca Cancer J. Clin. 50:2000;7-33.
2. Punnonen R., Teisala K., Kuoppala T., Bennett B., Punnonen J. Cytokine production profiles in the peritoneal fluids of patients with malign or benign gynecologic tumors. Cancer. 84:1998;788-796.
3. Takeyama H., Wakamiya N., O'Hara C., Arthur K., Niloff J., Kufe D., Sakarai K., Spri D. Tumor necrosis factor expression by human ovarian carcinoma in vivo. Cancer Res. 51:1991;4476-4480.
4. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNulty D., Blumenthal M.J., Heys J.R., Landvatter S.W., Strickler J.E., McLaughlin M.M., Siemens I.R., Fisher S.M., Livi G.P., White J.R., Adams J.L., Young P.R., protein A. kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 372:1994;739-746.
5. Rouse J., Cohen P., Trigon S., Morange M., Alonso-Llamazares A., Zamanillo D., Hunt T., Nebreda A.R. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell. 78:1994;1027-1037.
6. Woodgett J.R., Kyriakis J.M., Avruch J., Zon L.I., Zanke B., Templeton D.J. Reconstitution of novel signaling cascades responding to cellular stresses. Philos. Trans. R. Soc. Lond. B Biol. Sci. B. 351:1996;135-142.
7. Cuenda A., Rouse J., Doza Y.N., Meier R., Cohen P., Gallagher T.F., Young P.R., Lee J.C. SB203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364:1995;229-233.
8. Beyaert R., Cuenda A., Vanden Berghe W.V., Plaisance S., Lee J.C., Haegeman G., Cohen P., Fiers W. The p38/RK mitogen-activated protein kinase pathway regulated interleukin-6 synthesis in response to tumour necrosis factor. EMBO J. 15:1996;1914-1923.
9. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., Griswold D.E. Pharmacological profile of SB203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Therap. 279:1996;1453-1461.
10. Underwood D.C., Osbron R.R., Bochnowicz S., Webb E.F., Rieman D.J., Lee J.C., Romanic A.M., Adams J.L., Hay D.W., Griswold D.E. SB 239063, a p 38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. Lung Cell Mol. Physiol. 279:2000;L895-L902.
11. Lee J.C., Kumar S., Griswold D.E., Underwood D.C., Votta B.J., Adams J.L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology. 47:2000;185-201.
12. Fogh J. Human Tumor Cells in Culture. 1975;Plenum Press, New York.
13. Imamura H., Takao S., Aikou T. A modifiedinvasion-3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide assay for quantitating tumor cell invasion. Cancer Res. 54:1994;3620-3624.
14. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:2000;1306-1311.
15. Ellerbroek S.M., Halbleib J.M., Benavidez M., Warmka J.K., Wattenberg E.V., Stack M.S., Hudson L.G. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res. 61:2001;1855-1861.
16. Simon C., Goepfert H., Boyd D. Inhibition of the mitogen-activated protein kinase by SB203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res. 58:1998;1135-1138.
17. Bostrom P.J., Ravanti L., Reunanen N., Aaltonen V., Soderstrom K.O., Kahari V.M., Laato M. Expression of collagenase-3 (matrix-metalloproteinase 13) in transitional-cell carcinoma of the urinary bladder. Int. J. Cancer. 88:2000;417-423.
18. Ravanti L., Heino J., Lopez-Otin C., Kahari V.M. Induction of collagenase-3 (MMP-13) expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 mitogen-activated protein kinase. J. Biol. Chem. 274:1999;2446-2455.
19. Ravanti L., Toriseva M., Penttinen R., Crombleholme T., Foschi M., Han J., Kahari V.M. Expression of human collagenase-3 (MMP-13) by fetal skin fibroblasts is induced by transforming growth factor beta via p38 mitogen-activated protein kinase. FASEB J. 15:2001;1098-1100.
20. Brauchle M., Glück D., Di Padova F., Han J., Gram H. Independent role of p38 and Erk1/2 mitogen-activated kinases in the upregulation of matrix-metalloproteinase-1. Exp. Cell Res. 258:2000;135-144.
21. Westermarck J., Li S., Jaakkola P., Kallunki T., Grenman R., Kahari V.M. Activation of fibroblast collagenase-1 expression by tumor cells of squamous cell carcinomas is mediated by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase. Cancer Res. 24:2000;7156-7162.
22. Jiang Y., Chen C., Li Z., Guo W., Genger J., Lin S., Han J. Characterization of the structure and function of a new mitogen-activated protein kinase (p38β). J. Biol. Chem. 271:1996;17920-17925.
23. Wang X.S., Diener K., Manthey C.L., Wang S.W., Rosensweig B., Bray J., Delaney J., Cole C.N., Chan-Hui P.Y., Mantlo N., Lichenstein H.S., Zukowski M., Yao Z. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J. Biol. Chem. 272:1997;23668-23671.
24. Li Z., Jiang Y., Ulevich J., Han J. The primary structure of p38γ: a new member of the p38 group of MAP kinases. Biochem. Biophys. Res. Commun. 228:1996;334-337.
25. Kumar S., McDonnel P.C., Gum R.J., Hand A.T., Lee J.C., Young P.R. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specifity and sensitivity to inhibition by pyridinyl imidazoles. Biochem. Biophys. Res. Commun. 235:1997;553-557.
26. Davies S.P., Reddy H., Caivano M., Cohen P. Specifity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351:2000;95-105.
27. Lali F.V., Hunt A.E., Turner S.J., Foxwell B.M.J. The pyridinyl imidazole inhibitor SB 203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phophorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J. Biol. Chem. 275:2000;7395-7402.
28. Clerk A., Sugden P.H. The p38-MAPK inhibitorSB203580 inhibits cardiac stress-activated protein kinases/c-jun N-terminal kinases (SAPKs/JNKs). FEBS Lett. 426:1996;93-96.
29. Yazlovitskaya E.M., Pelling J.C., Persons D.L. Association of apoptosis with the inhibition of extracellular signal-regulated protein kinase activity in the tumor necrosis factor-resistant ovarian carcinoma cell line UCI 101. Mol. Carcinogenesis. 25:1999;14-20.